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Abstract 
Myelodysplastic syndromes (MDS) are stem cell disorders that can progress to acute 
myeloid leukemia (AML). While hematopoietic cell transplantation (HCT) can be 
curative, additional therapies are needed for a disease that disproportionally afflicts the 
elderly. We tested the ability of a CD16xCD33 bispecific killer cell engager (BiKE) to 
induce natural killer (NK) cell function from 67 MDS patients. Compared to age-matched 
normal controls, CD7
+
 lymphocytes, NK cells, and CD16 expression were markedly 
decreased in MDS patients. Despite this, reverse-antibody dependent cell-mediated 
cytotoxicity (R-ADCC) assays showed potent degranulation and cytokine production 
when resting MDS-NK cells were triggered with an agonistic CD16 mAb. Blood and 
marrow MDS-NK cells treated with BiKE significantly enhanced degranulation, TNF- 
and IFN- production against HL-60 and endogenous CD33+ MDS targets. MDS patients 
had a significantly increased proportion of immunosuppressive CD33
+
 myeloid derived 
suppressor cells (MDSC) that negatively correlated with MDS lymphocyte populations 
and CD16 loss on NK cells. Treatment with the CD16xCD33 BiKE successfully reversed 
MDSC immunosuppression of NK cells and induced MDSC target cell lysis. Lastly, the 
BiKE induced optimal MDS-NK cell function irrespective of disease stage. Our data 
suggest that the CD16xCD33 BiKE functions against both CD33
+
 MDS and MDSC 
targets and may be therapeutically beneficial for MDS patients. 
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INTRODUCTION 
MDS are clonal heterogeneous stem cell disorders characterized by normal or 
hypercellular bone marrow (BM) with peripheral blood (PB) cytopenias and an increased 
risk of progressing to frank AML
1
. The only curative treatment for MDS is HCT, 
although many patients are ineligible due to advanced age (median age at diagnosis is 70-
75 years)
1
, performance status and comorbidities. Accordingly, alternative therapies are 
offered, but due to the heterogeneous nature of MDS overall responses and duration of 
responses are suboptimal
2
. As a result, new therapeutic strategies are urgently needed to 
reduce MDS burden and improve overall survival.  
 
The ability of NK cells to control human hematologic malignancies has been increasingly 
recognized. Consequently, NK cells are acknowledged to play an important role in tumor 
immunosurveillance
3-5
. NK cell function is regulated by a repertoire of inhibitory and 
activating surface receptors
6
. NK cell killing can occur by distinct mechanisms that 
involve NKG2D and natural cytotoxicity receptors (NCR), which mediate natural 
cytotoxicity, or through the potent activating receptor CD16 (FcRIII) that mediates 
antibody dependent cell-mediated cytotoxicity (ADCC)
6-8
. NK cells from MDS patients 
show impairments in both natural cytotoxicity and cytokine production
9-11
. However, the 
ability of MDS-NK cells to function through CD16 to induce an ADCC response has not 
been investigated.  
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The therapeutic potential of manipulating NK cell function via CD16 for the treatment of 
cancer has been demonstrated through the use of monoclonal antibody (mAb) 
therapies
12,13
. Currently, novel single chain fragment variable (scFv) recombinant 
reagents termed bispecific and trispecific killer cell engagers (BiKE and TriKE), which 
specifically target CD16 expressed on effector NK cells and antigens-of-interest on tumor 
cells, are being developed and tested for clinical use
14-18
. We recently developed a novel 
BiKE that targets CD16 along with the myeloid differentiation antigen CD33 
(CD16xCD33) and demonstrated its ability to facilitate effective NK cell elimination of 
primary CD33
+
 AML targets
16
. Here, we tested the CD16xCD33 BiKE using primary 
MDS patient samples. We show that CD16 function is intact in MDS patients and can 
induce BiKE-mediated NK cell killing of CD33
+
 MDS targets and CD33
+
 
immunosuppressive MDSC targets. Our data demonstrate the therapeutic potential of the 
CD16xCD33 BiKE and suggest that this reagent may be efficacious in patients with 
MDS. 
 
METHODS 
Patient and Clinical Data Collection 
Patient samples, demographics and MDS pathology details were supplied by the NMDP 
and CIBMTR. De-identified samples and healthy controls were approved by the 
University of Minnesota
 
institutional review board in accordance with Declaration of 
Helsinki. Pathologic classification data were available in the FAB format (RA, RARS, 
RAEB, RAEB-T, and CMML), which shows the overlap between MDS and AML. Raw 
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cytogenetic data were available in the majority of patients (n=48). We further sub-
classified the raw cytogenetic data into the defined international prognosis scoring system 
(IPSS) classification categories of favorable (-Y, 20q, 5q-), poor (complex (≥3 
abnormalities) or chromosome 7 abnormalities), or intermediate (all others). Blast 
percentage at the time of transplant was also available and categorized by IPSS 
classification.  
 
Cell Isolation 
Peripheral blood mononuclear cells (PBMC) from MDS patients were collected pre-
transplant, prior to treatment and cryopreserved by the NMDP Research Repository. 
PBMC from age-matched normal donors (median age: 59 years, range: 22-80, 44% 
female, 56% male) were isolated from adult blood obtained from Memorial Blood Center 
(Minneapolis, MN) by centrifugation using a Histopaque gradient (Sigma-Aldrich, St. 
Louis, MO) and cryopreserved. Paired blood and marrow samples were obtained from the 
Leukemia Tissue Bank, a shared resource at the University of Minnesota. All samples 
were obtained after informed consent, using guidelines approved by the Committee on 
the Use of Human Subjects in Research at the University of Minnesota and the NMDP in 
accordance with the Declaration of Helsinki.  
 
Cell Lines  
The CD33
+
 human acute promyelocytic leukemia cell line HL-60 (ATCC, Manassas, 
VA) was cultured at 37C with 5% CO2 in Iscove’s medium (Invitrogen, Carlsbad, CA) 
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supplemented with 20% FBS (Gibco-Invitrogen) and 100U/mL penicillin and 100U/mL 
streptomycin (Invitrogen). The murine mastocytoma cell line P815 (ATCC) was cultured 
at 37C with 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM), high glucose 
(Invitrogen) supplemented with 10% FBS and 100U/mL penicillin and 100U/mL 
streptomycin.  
 
Cytokine-Derived MDSC Targets 
In vitro generation and characterization of cytokine-derived human MDSC targets from 
normal PBMC were performed as previously described
19
. The phenotype of in vitro 
cytokine-derived MDSC was evaluated by flow cytometry for the expression of CD45, 
CD33, CD11b, CD14 and HLA-DR. qRT-PCR was used for the evaluation of specific, 
differentiation-associated gene expression as previously described
19
. The ability to 
suppress the proliferation of CFSE-labeled (Invitrogen) allogeneic T and NK cells in 5 
day MDSC-co-cultures (effector:target (E:T) ratio = 1:2) was evaluated by flow 
cytometry as previously described
19
. 
 
Flow Cytometry 
Cells were immunophenotyped with the following fluorescent-labeled monoclonal 
antibodies (mAb) against: PE-Cy7-conjugated CD56 (HCD56; BioLegend, San Diego, 
CA), ECD-conjugated CD3 (UCHT1; Beckman Coulter, Brea, CA), APC-Cy7-
conjugated CD16 (3G8; BioLegend), PE-conjugated CD7 (M-T701; BD Biosciences, 
San Jose, CA), Pacific Blue-conjugated CD45 (HI30; BioLegend), FITC-conjugated CD2 
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(S5.2; BD Biosciences), PerCP-Cy5.5-conjugated anti-human CD107a (LAMP-1) 
(H4A3; BioLegend), Pacific Blue-conjugated anti-human IFN- (4S.B3; BioLegend), 
FITC-conjugated TNF- (MAb11; BioLegend), FITC-conjugated CD33 (P67.6; BD 
Biosciences), PE-conjugated CD11b/Mac-1 (ICRF44; BD Biosciences), APC-Cy7-
conjugated CD14 (M5E2; BioLegend), PE-Cy5-conjugated HLA-DR (L243; BioLegend) 
and APC-conjugated CD45 (HI30; BioLegend). Phenotypic acquisition of cells was 
performed on the LSRII (BD Biosciences) and analyzed with FlowJo software (Tree Star 
Inc., Ashland, OR). 
 
Construction, Expression and Purification of the bscFv CD16xCD33 BiKE 
The synthesis and assembly of hybrid genes encoding the CD16x33 BiKE reagent were 
accomplished by using DNA shuffling and DNA ligation techniques as previously 
described
16,20,21
. DNA-sequencing analysis (Biomedical Genomics Center, University of 
Minnesota) was used to verify that the gene was correct in sequence and cloned in frame. 
For bacterial protein expression and purification by ion exchange and size exclusion 
chromatography, methods were used as previously described
20
. 
 
Cytokine/Chemokine Production and Degranulation (CD107a) Assay  
Thawed PBMC from MDS patients and normal donors were incubated overnight at 37ºC, 
5% CO2 in basal medium or basal medium supplemented with IL-12 (10ng/mL) and IL-
18 (100ng/mL). Cells were then treated with the CD16xCD33 BiKE (10g/mL), 
scFvCD16 control reagent (10g/mL) or no reagent, co-cultured with (E:T ratio = 10:1) 
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or without HL-60 or cytokine-derived MDSC targets and CD107a expression and 
intracellular IFN- and TNF- production were evaluated as previously described16.  
 
51-Chromium Release Cytotoxicity Assay  
Cytotoxicity was evaluated by 4-hour 
51
Cr-release assays. Briefly, resting PBMC from 
normal donors treated with the CD16xCD33 BiKE (10g/mL), scFvCD16 control 
reagent (10g/mL) or no reagent were co-cultured for 4-hours with 51Cr-labeled 
cytokine-derived MDSC or HL-60 targets at varying E:T ratios. 
51
Cr release was 
measured by a gamma scintillation counter (Perkin Elmer, Walthman, MA) and specific 
target lysis was determined
16
.  
 
Reverse Antibody Dependent Cell-Mediated Cytotoxicity (R-ADCC) Assay 
Resting PBMC from MDS patients and normal donors were coated with 10g/mL of the 
following agonistic mAb in various combinations for 30 minutes at room temperature: 
anti-CD16 (3G8; BioLegend), anti-DNAM-1 (11A8; BioLegend), anti-CD2 (TS1/8; 
BioLegend), anti-2B4 (C1.7; BioLegend) and mIgG (MOPC-21; BioLegend). Coated 
PBMC were then co-cultured with P815 targets in basal medium for 4 hours at 37C with 
5% CO2 and CD107a expression and intracellular IFN- and TNF- production were 
evaluated as previously described
16
. 
 
Statistical Analysis 
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Grouped data were expressed as mean  standard error mean (SEM). Differences 
between two groups were analyzed by Student’s t test or the Mann-Whitney test. 
Differences between more than two groups were analyzed by two-way analysis of 
variance (ANOVA) followed by Bonferroni’s or Tukey-Kramer’s post-tests. Spearman’s 
rho tests were used to evaluate correlative relationships (GraphPad Prism Statistical 
Software, La Jolla, CA). 
 
RESULTS 
MDS Patient Characteristics 
MDS patient samples were collected pre-transplant, prior to treatment from a cohort 
undergoing adult unrelated donor allogeneic transplantation. Among the 67 MDS 
patients, 60% were male and 40% were female with a median age of 47 years (range, 19-
74). According to FAB classification 13% had refractory anemia (RA), 12% RA with 
ringed sideroblasts (RARS), 36% refractory anemia with excess blasts (RAEB), 15% 
refractory anemia with excess blasts in transformation (RAEB-T) and 24% were 
classified as other (Appendix Table 1). Based on data available from the era of sample 
collection (1990-2005), 48 patients had cytogenetic data available and could be stratified 
by an IPSS cytogenetic classification (36% of patients had a favorable karyotype, 15% 
intermediate and 22% poor) and 57 patients had blast percentage at date of transplant data 
available and could be stratified by IPSS categories (52% of patients had <5% blasts, 
21% had 5-10% blasts, 4% had 11-20% blasts and 8% had ≥21% blasts).  
 
 8 
NK cells and their CD16 expression are significantly decreased in MDS patients 
PBMC populations from normal donors and MDS patients were analyzed by flow 
cytometry to determine the frequencies of CD7
+
 lymphocytes, CD56
-
/CD3
+
 T cells, 
CD56
+
/CD3
+
 NKT cells and CD56
+
/CD3
-
 NK cells (Figure 1A and 1B). Compared to 
normal donors, MDS patients had a significant decrease in CD7
+
 lymphocytes, T and NK 
cells while no significant difference was observed for the NKT population (Figure 1C, 
Appendix Figure 1A and Table 1). Further evaluation of the NK cell CD56
bright
 and 
CD56
dim
 subpopulations did not reveal any significant differences between normal donors 
and MDS patients (Table 1). CD16 expression was significantly decreased on MDS NK 
cells compared to normal donor PB-NK cells (Percent: 633% vs. 892%; MFI: 
1169177 vs. 5470656; p < 0.0001; Figure 1D and Appendix Figure 1B). 
 
Activation of NK cells through CD16 is intact in MDS patients 
An agonistic mAb against CD16 was used to induce NK cell function in a R-ADCC 
assay. Compared to the IgG control, CD16 crosslinking of resting MDS-NK cells led to a 
significant increase in degranulation (162% vs. 465%, p < 0.0001, n=16), which was 
similarly observed in normal donors (111% vs. 463%, p < 0.0001, n=12; Figure 2A). 
Intracellular cytokine production induced via CD16 triggering was evaluated and a 
comparison of MDS patients to normal donors did not show any significant differences in 
TNF- (MDS: 92% vs. normal: 61%, p = 0.331; Figure 2B) or IFN- (61% vs. 
102%, p = 0.113; Figure 2C) production further demonstrating the ability of MDS-NK 
cells to function through CD16 despite the lower expression levels. Activation of resting 
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NK cells occurs via synergistic interactions between CD16 and the co-activating 
receptors DNAM-1, CD2 and 2B4
22
. To further evaluate the function of CD16 on MDS-
NK cells, CD16 was co-crosslinked in pairwise combinations and function was 
measured. Compared to the IgG control, all receptor combinations with CD16 induced 
significant increases in CD107a expression (Figure 2A), TNF- (Figure 2B) and IFN- 
(Figure 2C) production in MDS-NK cells. No significant differences in degranulation and 
TNF- production induced by co-crosslinking receptor pairs were observed between 
normal donors and MDS patients. However, MDS-NK cells displayed a significant 
decrease in IFN- production compared to normal donor NK cells for CD16 crosslinking 
combinations with DNAM-1, CD2 and 2B4. No differences in DNAM-1, CD2 and 2B4 
receptor expression were observed between normal donor and MDS-NK cells (Appendix 
Figure 2). To evaluate whether the diminished IFN- production by MDS-NK cells was 
specific to CD16 synergistic activation, resting MDS-NK cells were stimulated overnight 
with saturating concentrations of IL-12 and IL-18. Compared to normal donors, MDS-
NK cells displayed a significant reduction in IFN- production in response to cytokine 
stimulation (Appendix Figure 3) revealing a broader defect in the activation threshold for 
the IFN- pathway.  
 
CD16xCD33 BiKE enhances NK cell activity against primary CD33
+
 MDS targets 
To evaluate the therapeutic potential of targeting CD16 in MDS patients, PBMC from 
normal donors and MDS patients were treated with the CD16xCD33 BiKE, scFv CD16 
control or no reagent and co-cultured with the CD33
+
 HL-60 cell line. NK cell 
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degranulation and TNF- and IFN- production were then evaluated by flow cytometry. 
Compared to the no reagent and scFv CD16 controls, MDS-NK cell degranulation 
(Figure 3A), TNF- (Figure 3B) and IFN- (Figure 3C) production were significantly 
increased. Moreover, in the absence of HL-60 targets, MDS-NK cells treated with the 
CD16xCD33 BiKE targeted endogenous CD33
+
 cells, significantly enhancing 
degranulation (Figure 3D) and TNF- (Figure 3E) and IFN- (Figure 3F) production. As 
with CD16 synergistic crosslinking and IL-12 and IL-18 stimulation, CD16xCD33 BiKE 
stimulation of MDS-NK cells resulted in lower levels of IFN- production in the presence 
(Figure 3C) and absence (Figure 3F) of HL-60 targets compared to normal donors. 
 
The CD33
+
 MDSC population is significantly increased in MDS patients and 
negatively correlates with MDS lymphocyte populations 
Suppressive MDSC are phenotypically defined as CD33
+
/CD11b
+
/CD14
-
/HLA-DR
lo/-
 
and are increased during oncogenesis and in the presence of inflammatory cytokines
23
. 
We, therefore, evaluated the presence of MDSC in MDS. Within the all cell fraction, the 
total CD33
+
 cell population frequency was significantly higher in MDS patients 
compared to normal donors (292% vs. 162%, p = 0.002; Table 1). CD7+ lymphocytes, 
T and NK cells from normal donors and MDS patients lacked expression of CD33 
(Appendix Figure 4A-4E). Additional sub-gating within the CD33
+
 fraction showed a 
distinct MDSC population in MDS patients that was not observed in normal donors 
(Appendix Figure 5), where MDS-MDSC comprised 212% of the total CD33+ cell 
fraction (vs. normal: 0.70.1%, p < 0.0001) and 61% of the all cell fraction (vs. 
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0.10.02%, p < 0.0001; Figure 4A). The relationships between MDSC and lymphocyte 
populations were next evaluated in MDS patients.  Among all MDS patients, there was a 
statistically significant negative correlation between percent MDSC and percent CD7
+
 
lymphocytes, T cells, NKT cells and NK cells (Figure 4B). Interestingly, when stratifying 
the MDS patients by disease status, a statistically significant stronger negative correlation 
was observed between MDSC and NK cells (r = -0.6104, p < 0.01) for lower risk MDS 
patients, whereas no significant correlations were observed for CD7
+
 lymphocytes, T and 
NKT cells (Figures 4C). Among higher risk MDS patients there were significant negative 
correlations between MDSC and CD7
+
 lymphocytes, T and NKT cell populations (Figure 
4D). Moreover, a statistically significant negative correlation between MDS-MDSC and 
MDS-NK cell CD16 expression was also observed (Appendix Figure 6), suggestive of a 
MDSC immunosuppressive mechanism against NK cells. Taken together, these findings 
support a negative relationship between the MDSC population and lymphocyte 
populations in MDS patients and further support the evidence that immunosuppressive 
MDSC help facilitate ineffective hematopoiesis in MDS
24
. 
 
Immunosuppressive MDSC are targeted by the CD16xCD33 BiKE 
MDSC have been shown to suppress NK cell activity
25,26
, therefore, we next evaluated 
the ability of the CD16xCD33 BiKE to activate NK cells in the presence of 
immunosuppressive MDSC. Cytokine-derived MDSC were generated from PBMC 
isolated from normal donors and post-induction characterization analysis verified the 
MDSC phenotype and gene expression signature (data not shown). Cytokine-derived 
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MDSC functioned to suppress T cell (Appendix Figure 7A) and NK cell proliferation 
(Figure 5A). The MDSC targets were then labeled with 
51
Cr and co-cultured with normal 
donor resting NK cells in the absence or presence of the CD16xCD33 BiKE or scFv 
CD16 control. Without reagent treatment or when treated with the scFv CD16 control, 
NK cell cytotoxicity was suppressed in the presence of MDSC targets. However, when 
treated with the CD16xCD33 BiKE, there was a significant increase in MDSC killing 
(CD16xCD33 BiKE vs. no reagent: (20:1) 635% vs. 72%, p < 0.0001; Figure 5B). 
Evaluation of NK cell degranulation and intracellular cytokine production revealed 
significant increases in CD107a expression (Figure 5C), TNF- (Figure 5D) and IFN- 
(Figure 5E) production as well in the presence of MDSC targets when resting NK cells 
were treated with the CD16xCD33 BiKE. We next evaluated the ability of the 
CD16xCD33 BiKE to enhance PB and BM MDS-NK cell function against MDSC 
targets. Significant increases in degranulation (Figure 5F), TNF- (Figure 5G) and IFN- 
(Figure 5H) production were observed in the presence of the BiKE. Similar results were 
found using HL-60 targets (Appendix Figures 7B-7D). Notably, no significant 
differences were observed between PB and BM MDS-NK cell BiKE-mediated function. 
Overall, these data demonstrate the ability of the CD16xCD33 BiKE to induce blood and 
marrow MDS-NK cell activation to overcome MDSC immunosuppression.  
 
CD16xCD33 BiKE-enhanced NK cell activity functions regardless of MDS disease 
stage 
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MDS is a heterogeneous disease and treatment options depend on several clinical factors 
specific to each patient. Therefore, the ability of the CD16xCD33 BiKE to enhance NK 
cell function among the various MDS groups stratified by clinical features was evaluated. 
No significant differences in NK cell (Figure 6A), total CD33
+
 (Figure 6B) and MDSC 
(Figure 6C) population frequencies were observed among FAB classification and IPSS 
karyotype groups in MDS patients. Upon evaluation of CD16xCD33 BiKE-induced 
MDS-NK cell function (degranulation, TNF- and IFN- production) in the absence of 
HL-60 targets (Figure 6D) and in the presence of HL-60 targets (Figure 6E), no 
significant differences between MDS groups were observed. Stratifying by blast 
percentage also showed no significant differences in the study variables (Appendix Table 
2). As the median age of our patient cohort indicated a younger population, respectively, 
the study variables were also stratified by age to evaluate a potential age effect. No 
significant differences were observed in percent NK cells, total CD33
+
 cells, MDSC or 
CD16xCD33 BiKE-induced NK cell function among age strata in MDS patients 
(Appendix Figure 8). Altogether these data indicate that despite disease heterogeneity, 
the CD16xCD33 BiKE can consistently function to enhance MDS-NK cell activity 
against the CD33
+
 target cell population, which includes immunosuppressive MDSC, 
regardless of disease stage. 
 
DISCUSSION 
We examined the expression and function of CD16 on MDS-NK cells and the ability of a 
CD16xCD33 BiKE to mediate MDS-NK cell targeting of the CD33
+
 cell population that 
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contains both the premalignant clone and immunosuppressive MDSC. Previous studies of 
MDS-NK cells from PB and BM have evaluated NK cell function in the context of 
natural cytotoxicity mediated by NKp46, NKp30, NKG2D, 2B4 and DNAM-1
9-11
.  
Kiladjian et al. described decreased cytolytic function of PB NK cells from all MDS 
subtypes against K562 targets despite normal expression of natural cytotoxicity receptors, 
as well as decreased IFN- and TNF- secretion in response to IL-2 stimulation9. In 
contrast, Epling-Burnette et al. observed down-regulation of NKp30 and NKG2D and 
correlated PB MDS-NK cell dysfunction with decreased NKG2D expression
10
.  In 
another study, Carlsten et al. found significant decreases in DNAM-1 and NKG2D 
expression in BM MDS-NK cells that were not observed in PB MDS-NK cells; despite 
this difference, both sources of MDS-NK cells displayed impaired degranulation in the 
presence of K562 cells and in a R-ADCC assay triggering through NKG2D, 2B4 and 
DNAM-1
11
. Our study demonstrated that despite reduced CD16 expression on MDS-NK 
cells, degranulation and TNF- and IFN- production could be induced through CD16 
stimulation by an agonistic mAb and the CD16xCD33 BiKE, indicating a functional 
ADCC response in MDS patients. This agrees with early evidence that showed an intact 
lymphocyte ADCC response in patients with primary preleukemic syndrome (PPS) while 
abnormalities in other lymphocyte functions were observed
27
.  Notably, when we co-
crosslinked MDS-NK cells with pairwise combinations of CD16 and co-activating 
receptors, synergistic activation was significantly diminished for IFN- production, but 
not degranulation or TNF- production. Decreases in IFN- production were also found 
when MDS-NK cells were stimulated with IL-12 and IL-18 and the CD16xCD33 BiKE. 
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Our data agree with previous work that showed decreased NK cell IFN- production 
despite stimulation with IL-12 and IL-18 in the context of a murine hepatic tumor model 
containing immunosuppressive MDSC
25
. Importantly, however, we demonstrate 
cytotoxicity was not impaired in MDS patients and could be driven by CD16xCD33 
BiKE stimulation. Fauriat et al. has demonstrated that NK cell IFN- production has a 
greater threshold of activation than that of degranulation and TNF- production28. Our 
data, therefore, suggest NK cell functions that have a lower threshold of activation are 
intact in MDS patients while the higher activation threshold required for stimulation of 
the IFN- pathway may be impaired. 
 
Increases in the frequency of circulating MDSC have been well described in solid tumors 
and studies have shown MDSC are an important factor in facilitating immune evasion 
and tumor progression
23,29-32
.  While the roles of MDSC in hematologic malignancies are 
still evolving, a recent study demonstrated an increase in MDSC frequency in the PB of 
multiple myeloma (MM) patients that increased with disease progression and promoted 
tumor growth via suppression of CD4
+
 T, CD8
+
 T and NKT cell lymphocyte 
populations
33
. We demonstrated here that the percent of MDSC is significantly increased 
in the PB of MDS patients and negatively correlates with CD7
+
 lymphocytes, T, NKT 
and NK cell populations. Interestingly, when MDS patients were stratified by disease 
status, this negative relationship was only significant for NK cells in patients with lower 
risk. By contrast, the negative correlations between MDSC and total lymphocytes, T and 
NKT cells were significant for patients with higher risk. MDSC are generated from 
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immature myeloid cells, which includes immature dendritic cells (DC)
23
. The crosstalk 
between NK cells and DC has been well studied and it has been shown that NK cells play 
a role in DC maturation via the secretion of TNF- and IFN- as well as cell-to-cell 
contact mechanisms that involve NKp30
34-37
. Expansion and activation of MDSC require 
several different factors that include TNF- and IFN-38-41. As our data show a 
statistically significant negative correlation between MDSC and NK cells for lower risk 
disease, it is possible the altered BM microenvironment in MDS primes the induction and 
expansion of immature DC to MDSC and interaction with NK cells promotes MDSC 
functional activation via NK cell secretion of TNF- and IFN-, which in turn ultimately 
leads to suppression of the enabling NK cells. Moreover, studies have shown activated 
MDSC promote the development and expansion of T regulatory (Treg) cells
42-44
, which is 
a characteristic of MDS patients with advanced disease
45-47
. This supports our data 
showing a statistically significant negative correlation between MDSC and T cells in 
MDS patients with higher risk. Taken together, these data suggest a potential model 
whereby interactions early in disease between MDSC-primed immature myeloid cells and 
NK cells promote the functional activation of MDSC, leading to suppression of this 
innate lymphocyte population and promotion of Treg cell development, which ultimately 
function in concert with MDSC to suppress adaptive immunity and facilitate disease 
progression. Further studies are underway to investigate this hypothesis. 
 
MDSC use multiple mechanisms to suppress antitumor immunity. Down-regulation of L-
selectin (CD62L) on T cells has been shown to impair T cell homing to lymph nodes and 
 17 
activation
23
. Hanson et al. demonstrated MDSC constitutively express the sheddase 
ADAM 17 (a disintegrin and metalloproteinase domain 17) on their plasma membrane 
and suggest ADAM 17 is the enzyme responsible for cleaving the ectodomain of L-
selectin
48
. We recently demonstrated that NK cell CD16 surface expression is regulated 
by ADAM 17, which functions to promote attenuation of NK cell function through 
cleavage of CD16 from the cell surface
49
. We show here a statistically significant 
negative correlation between MDSC and MDS-NK cell expression of CD16 suggesting a 
novel role for MDSC suppression of NK cell function, namely the induction of NK cell 
CD16 shedding. Accordingly, further testing of an ADAM 17 inhibitor in combination 
with the CD16xCD33 BiKE in MDS is warranted and may further serve to inhibit MDSC 
immunosuppression and enhance NK cell effector function against CD33
+
 targets.  
 
Immune suppression has a crucial role in promoting tumor progression and the 
supporting data clearly indicate that elimination of suppressing factors is required for 
cancer immunotherapies to be successful
50
. Our data and others suggest that MDSC 
contribute to ineffective hematopoiesis in MDS
24
. Thus, the ability to target this 
immunosuppressive population through the CD16xCD33 BiKE may be therapeutically 
beneficial for patients with MDS and other diseases characterized by increased MDSC. 
Acknowledging that the CD16xCD33 BiKE can also target normal CD33
+
 cells 
(monocytes and committed myeloid progenitors), transient myelosuppression may be 
expected with this therapy, not unlike most cytotoxic therapies. Clinical trials show 
CD3xCD19 BiTE therapy is efficacious for ALL while targeting of the normal cell 
 18 
compartment is well tolerated
51-53
. This is in part due to the ease with which drug 
exposure can be managed; an important feature that helps control on-target/off-tumor 
effects allowing regeneration of the normal cell compartment after drug elimination. 
Moreover, for NK cells, other receptor-ligand interactions, facilitated by the BiKE-
mediated effector-target cell synapse, may play an important role in target cell 
elimination. In conclusion, we propose that CD16xCD33 BiKE is a promising therapy for 
MDS and other myeloid malignancies. 
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TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPercent of all cells based on FSC/SSC gate excluding debris 
bPercent of CD7+/CD56+/CD3- NK cell population 
Normal MDS P-value
Sample Size (n) 20 67
aCD45+/SSC lo (Non-myeloid) 74 ± 2% 50 ± 2% <0.0001
aCD45+/CD7+ Lymphocytes 54 ± 3% 25 ± 2% <0.0001
aCD56+/CD3- NK Cells   6 ± 1%   2 ± 0.3% <0.0001
    bCD56+bright/CD3- NK Cells   9 ± 2% 10 ± 2% 0.84
    bCD56+dim/CD3- NK Cells 90 ± 2% 89 ± 2% 0.85
aCD56+/CD3+ NKT Cells   1 ± 0.2%   1 ± 0.1% 0.61
aCD56-/CD3+ T Cells 40 ± 3% 20 ± 2% <0.0001
aCD45+/SSChi (Myeloid) 21 ± 2% 36 ± 3% 0.001
aCD33+ 16 ± 2% 29 ± 2% 0.002
aMDSCs (CD33+/CD11b+/CD14-/HLA-DRlo/-) 0.1 ± 0.02%   6 ± 1% <0.0001
Table 1: Summary of MDS PBMC Population Frequencies 
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Figure 1 
Figure 1: Aberrant NK cell frequency and NK cell CD16 expression in MDS PBMC.  
(A-C) PBMC from normal donors and MDS patients were stained with anti-CD56, anti-CD3, and anti-CD16 mAbs. (A-B) Gating strategy for the 
evaluation of the lymphocyte populations in normal donors (A) and MDS patients (B). Plots are representative from one normal donor (#12 of 20) 
and one higher risk MDS patient (#49 of 67) and gate frequency indicates population percent normalized to the all cell fraction based on the 
FSC/SSC gate excluding debris. (C) Percent of CD56
-
/CD3
+
 T cells and CD56
+
/CD3
-
 NK cells (normalized to all cell fraction based on the 
FSC/SSC gate excluding debris) and (D) percent of CD16
+
 NK cells (calculated as the percent of CD56
+
/CD3
-
 NK cells) as well as Mean 
Fluorescence Intensity (MFI) of CD16 expression on NK cells were determined by FACS analysis (****P<0.0001). 
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Figure 2 
Figure 2: NK cell activation induced through CD16 crosslinking is intact in MDS-NK cells.  
(A-C) Resting PBMC from normal donors and MDS patients were coated with 10g/mL of the indicated 
mAbs, co-cultured with P815 targets and a R-ADCC assay was performed. NK cell CD107a expression 
(A) and intracellular TNF- (B) and IFN- (C) production were evaluated by FACS analysis (*P<0.05, 
***P<0.001, ****P<0.0001). 
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Figure 3 
Figure 3: CD16xCD33 BiKE enhances MDS-NK cell function against CD33
+
 targets.  
(A-F) Resting PBMC from normal donors and MDS patients were coated with 10g/mL of the 
CD16xCD33 BiKE or scFv CD16 control and co-cultured with (A-C) or without (D-F) CD33
+
 HL-60 
targets. NK cell CD107a expression and intracellular TNF- and IFN- production were evaluated by 
FACS analysis (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). 
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Figure 4: MDS patients have a significant increase in MDSC that negatively correlates 
with lymphocyte populations.  
(A) PBMC from normal donors and MDS patients were stained with anti-CD45, anti-CD33, anti-CD11b, 
anti-CD14 and anti-HLA-DR mAbs and the percent of MDSC (phenotypically defined as 
CD33
+
/CD11b
+
/CD14
-
/HLA-DR
lo/-
) of the all cell fraction was evaluated (****P<0.0001). (B-D) Based 
on the all cell fraction, the correlation between % MDSC and % CD7
+
 lymphocytes, % T cells, % NKT 
cells and % NK cells among all MDS patients (B), lower risk MDS patients (C) and higher risk MDS 
patients (D). Correlation coefficients (r) and statistical significance are indicated in the figure. 
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NK Cell Proliferation 
Figure 5 
Figure 5: CD16xCD33 BiKE enhances NK cell cytotoxicity and cytokine production against MDSC targets.  
(A) CFSE-labeled NK cells were cultured for 5 days in basal medium or medium supplemented with 10ng/mL IL-15 in the presence or absence (E:T 
ratio = 1:2) of cytokine-derived MDSC from normal PBMC and proliferation was evaluated via FACS analysis. Histogram plots represent one of six 
normal donors. (B) PBMC from normal donors were coated with 10g/mL of CD16xCD33 BiKE or scFv CD16 control, co-cultured with cytokine-
derived MDSC or HL-60 targets and NK cell-mediated cytotoxicity was evaluated via a 
51
Cr-release assay (****P<0.0001, (n=4)). (C-E) PBMC from 
normal donors were coated with 10g/mL of CD16xCD33 BiKE or scFv CD16 control, co-cultured with cytokine-derived MDSC or HL-60 targets 
and NK cell CD107a expression and intracellular TNF- and IFN- production were evaluated via FACS analysis (**P<0.01, ****P<0.0001, (n=6)). 
(F-H) Mononuclear cells from paired peripheral blood (PB) and bone marrow (BM) samples were isolated from normal donors (n=4) and MDS 
patients (n=10), coated with 10g/mL of CD16xCD33 BiKE or scFv CD16 control, co-cultured with cytokine-derived MDSC and NK cell (F) CD107a 
expression and intracellular (G) TNF- and (H) IFN- production were evaluated via FACS analysis (*P<0.05, **P<0.01, ***P<0.01, ****P<0.0001). 
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Figure 6: CD16xCD33 BiKE consistently enhances NK cell function at all disease stages.  
The percent of CD56
+
/CD3
-
 MDS-NK cells (A), total CD33
+
 cells (B) and MDS-MDSC (C) of the all 
cell fraction was stratified according to their respective FAB classification and IPSS karyotype groups. 
(D-E) CD16xCD33 BiKE-induced MDS-NK cell functions (degranulation (CD107a), intracellular 
TNF- and IFN- production) in the absence of HL-60 targets (D) and in the presence of HL-60 targets 
(E) were stratified according to their respective FAB classification and IPSS karyotype groups. Y-axis 
of graphs (D and E) represent the percent of NK cells positive for each function listed in graph legend. 
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Appendix Table 1: Demographics of the MDS Patient Cohort 
 Abbreviations: FAB: French-American-British 
classification; RAEB-T: Refractory anemia with excess 
blasts in transformation; RAEB: Refractory anemia 
with excess blasts; RARS: Refractory anemia with 
ringed sideroblasts; RA: Refractory anemia; IPSS: 
International prognosis scoring system. 
 
aMedian (range) age at date of transplant 
 
bOther: Paroxysmal nocturnal hemoglobinuria; 
Polycythemia vera; Essential thrombocythemia; 
Myelofibrosis with myeloid metaplasia; Myelofibrosis or 
myelosclerosis; Myelodysplasia or myloproliferative 
disorder. 
 
cFavorable: normal karyotype, isolated –Y, del(5q) or 
del(20q); Intermediate: other abnormalities; Poor: 
complex (≥3 abnormalities) or chromosome 7 
anomalies. 
 
dBlast percentage at date of transplant 
 
eLower Risk: RA or RARS; Higher Risk: RAEB, RAEB-
T or CMML. Data regarding specific cell counts were 
not available, thus we were unable to determine the 
overall IPSS scores 
Variables No. of Patients (%)
Sex
  Male 40 (60%)
  Female 27 (40%)
aAge (years) 47 (19-74)
Ethnicity
  Caucasian 62 (93%)
  African-American   2 (3%)
  Hispanic   2 (3%)
  Other   1 (1%)
FAB Subtype
  RAEB-T 10 (15%)
  RAEB 24 (36%)
  RARS   8 (12%)
  RA   9 (13%)
 bOther 16 (24%)
cKaryotype (IPSS)
  Favorable 24 (36%)
  Intermediate   9 (14%)
  Poor 15 (22%)
  Unknown 19 (28%)
dBlast Percentage (IPSS)
  <5% 35 (52%)
  5 - 10% 14 (21%)
  11 - 20%   3 (4%)
  ≥21%   5 (8%)
  Unknown 10 (15%)
eMDS Status
  Lower Risk 24 (36%)
  Higher Risk 41 (61%)
  Unknown   2 (3%)
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Appendix Table 2: MDS cell population frequencies and CD16xCD33 BiKE-induced MDS NK cell 
function stratified by blast percentage (IPSS) 
 
<5% 
(n=35)
5-10% 
(n=14)
11-20% 
(n=3)
≥21% 
(n=5)
Unknown 
(n=10)
% NK cells 2 ± 0.3% 3 ± 1% 0.2 ± 0.1% 2 ± 1% 1 ± 0.3%
% CD33+ 28 ± 3% 29 ± 6% 56 ± 12% 23 ± 7% 28 ± 7%
% MDSC 21 ± 3% 23 ± 4% 38 ± 9% 20 ± 6% 14 ± 3%
bPBMC Alone
% CD107a + 38 ± 3% 33 ± 5% 33 ± 18% 30 ± 6% 42 ± 4%
% TNF-α+ 4 ± 1% 5 ± 2% 5 ± 4% 6 ± 4% 4 ± 1%
% IFN-γ+ 5 ± 1% 3 ± 0.4% 7 ± 3% 4 ± 1% 2 ± 1%
cPBMC + HL-60
% CD107a + 42 ± 2% 42 ± 4% 34 ± 17% 46 ± 3% 45 ± 4%
% TNF-α+ 11 ± 2% 12 ± 2% 13 ± 8% 17 ± 4% 16 ± 2%
% IFN-γ+ 14 ± 2% 13 ± 2% 9 ± 5% 23 ± 6% 18 ± 3%
aBlast percentage at date of transplant
bCD16xCD33 BiKE induced MDS-NK cell function in the absence of HL-60 targets
cCD16xCD33 BiKE induced MDS-NK cell function in the presence of HL-60 targets
aBlast Percentage (IPSS)
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Appendix Figure 1: NKT cell frequency and NK cell CD16 expression among MDS 
patients.  
(A) Percent of CD56
+
/CD3
+
 NKT cells (normalized to all cell fraction based on the FSC/SSC gate 
excluding debris). (B) Normal donor and MDS-NK cells were stained with anti-CD45, anti-CD7, anti-
CD56, anti-CD3 and anti-CD16 mAb and analyzed by flow cytometry. Representative flow cytometry 
plots from one normal donor (#14) and one higher risk MDS patient (#31) of percent of CD16
+
 NK cells 
are shown.  
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Appendix Figure 2: DNAM-1, 2B4 and CD2 MDS-NK cell receptor expression.  
Normal donor and MDS-NK cells were stained with anti-CD45, anti-CD7, anti-CD56, anti-CD3, anti-DNAM-1, anti-2B4 and anti-CD2 mAb and surface 
receptor expression of DNAM-1, 2B4 and CD2 on NK cells were evaluated by flow cytometry. 
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Appendix Figure 3: IFN- production of MDS-NK cells is lower compared to normal donors 
after IL-12 and IL-18 activation.  
PBMC from normal donors and MDS patients were stimulated overnight with IL-12 (10ng/mL) and IL-18 
(100ng/mL) and NK cell intracellular IFN- production was evaluated via FACS analysis (*P<0.05). 
  37 
 
 
 
Appendix Figure 4: CD33 Expression on lymphocyte populations.  
Bone marrow (BM) and peripheral blood (PB) from normal donors and MDS patients were stained with anti-CD45, anti-CD7, anti-CD56, anti-CD3 and anti-
CD33 and CD33 expression was evaluated by flow cytometry on CD7
+
, T and NK cell populations. Flow cytometry plots are representative of one normal 
donor and one MDS patient and show CD33 expression on (A) CD56
-
/CD3
+
 T cells and (B) CD56
+
/CD3
-
 NK cells. Aggregate data for CD33 expression on 
(C) CD7
+
 lymphocytes, (D) T cells and (E) NK cells from normal donors (n=2) and MDS patients (n=5) from BM and PB are shown. 
A B 
C D E 
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Appendix Figure 5: MDSC gating strategy.  
PBMC from normal donors and MDS patients were stained with anti-CD45, anti-CD33, anti-CD11B, anti-CD14 and anti-HLA-DR mAbs. (A-B) Gating strategy 
for the evaluation of MDSC population in normal donors (A) and MDS patients (B). Plots are representative from one normal donor (#3 of 20) and one higher 
risk MDS patient (#25 of 67) and gate frequency indicates population percent normalized to the all cell fraction based on the FSC/SSC gate excluding debris. 
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Appendix Figure 6: MDS-NK cell CD16 expression negatively correlates with MDS-MDSC frequency.  
PBMC from MDS patients were stained with anti-CD45, anti-CD7, anti-CD56, anti-CD3, anti-CD16, anti-CD33, anti-CD11b, anti-CD14 and anti-HLA-DR 
mAbs. The correlations between % MDSC (normalized to all cell fraction excluding debris) and % NK cells CD16
+
 among all MDS patients, lower risk MDS 
patients and higher risk MDS patients are presented. Correlation coefficients (r) and statistical significance are indicated in the figure. 
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Supplemental Figure 7: CD16xCD33 BiKE enhances peripheral blood and bone marrow NK cell function against HL-60 targets.  
(A) CFSE-labeled T cells were cultured for 5 days in basal medium, medium supplemented with 100U/mL IL-2 and CD3 bead activation in the presence or 
absence (E:T ratio = 1:2) of cytokine-derived MDSC from normal PBMC and proliferation was evaluated via FACS analysis. Histogram plots represent one 
of six normal donors. (B-D) Mononuclear cells from peripheral blood (PB) and bone marrow (BM) were isolated from normal donors (n=2) and MDS 
patients (n=5), coated with 10g/mL of CD16xCD33 BiKE or scFv CD16 control, co-cultured with HL-60 targets and NK cell (B) CD107a expression and 
intracellular (C) TNF- and (D) IFN- production were evaluated via FACS analysis (*P<0.05, **P<0.01). 
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Appendix Figure 8: CD16xCD33 BiKE consistently enhances MDS-NK cell function among 
all age strata.  
The percent of CD56
+
/CD3
-
 MDS-NK cells (A), total CD33
+
 cells (B) and MDS-MDSC (C) of the all cell 
fraction was stratified according to age groups (years). (D-E) CD16xCD33 BiKE-induced MDS-NK cell 
functions (degranulation (CD107a), intracellular TNF- and IFN- production) in the absence of HL-60 
targets (D) and in the presence of HL-60 targets (E) were stratified according to age groups. Y-axis of 
graphs (D and E) represent the percent of NK cells positive for each function listed in graph legend. 
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